Oncolytic measles virus retargeting by ligand display

Methods in Molecular Biology

Volumn 797, Issue , 2012, Pages 141-162

  Msaouel, Pavlos ^a   Iankov, Ianko D ^a   Allen, Cory ^a   Russell, Stephen J ^a   Galanis, Evanthia ^a  

^a MAYO CLINIC   (United States)

Author keywords

Measles engineering; Measles retargeting; Oncolytic measles virus; Virotherapy

Indexed keywords

LIGAND; MEASLES VACCINE; ONCOLYTIC VIRUS;

ANIMAL; ARTICLE; CERCOPITHECUS; DRUG SCREENING; GENE VECTOR; GENETICS; HUMAN; MEASLES VIRUS; METASTASIS; METHODOLOGY; MOUSE; NEOPLASM; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; TUMOR CELL LINE; VERO CELL; VIRUS REPLICATION;

ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; GENETIC VECTORS; HUMANS; LIGANDS; MEASLES VACCINE; MEASLES VIRUS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VERO CELLS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MEASLES VIRUS;

EID: 80555144263     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-340-0_11     Document Type: Chapter

References (37)

1. Peng, K. W., TenEyck, C. J., Galanis, E., Kalli, K. R., Hartmann, L. C., and Russell, S. J. (2002) Intraperitoneal therapy of ovarian cancer using an engineered measles virus, Cancer research 62, 4656–4662.
2. Hasegawa, K., Pham, L., O’Connor, M. K., Federspiel, M. J., Russell, S. J., and Peng, K. W. (2006) Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter, Clin Cancer Res 12, 1868–1875.
3. Phuong, L. K., Allen, C., Peng, K. W., Giannini, C., Greiner, S., TenEyck, C. J., Mishra, P. K., Macura, S. I., Russell, S. J., and Galanis, E. C. (2003) Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme, Cancer research 63, 2462–2469.
4. Peng, K. W., Ahmann, G. J., Pham, L., Greipp, P. R., Cattaneo, R., and Russell, S. J. (2001) Systemic therapy of myeloma xenografts by an attenuated measles virus, Blood 98, 2002–2007.
5. Dingli, D., Peng, K. W., Harvey, M. E., Greipp, P. R., O’Connor, M. K., Cattaneo, R., Morris, J. C., and Russell, S. J. (2004) Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter, Blood 103, 1641–1646.
6. Grote, D., Russell, S. J., Cornu, T. I., Cattaneo, R., Vile, R., Poland, G. A., and Fielding, A. K. (2001) Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice, Blood 97, 3746–3754.
7. McDonald, C. J., Erlichman, C., Ingle, J. N., Rosales, G. A., Allen, C., Greiner, S. M., Harvey, M. E., Zollman, P. J., Russell, S. J., and Galanis, E. (2006) A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer, Breast cancer research and treatment 99, 177–184.
8. Iankov, I. D., Msaouel, P., Allen, C., Federspiel, M. J., Bulur, P. A., Dietz, A. B., Gastineau, D., Ikeda, Y., Ingle, J. N., Russell, S. J., and Galanis, E. (2009) Demonstration of antitumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model, Breast cancer research and treatment 2010 Aug;122(3), 745–54.
9. Msaouel, P., Iankov, I. D., Allen, C., Morris, J. C., von Messling, V., Cattaneo, R., Koutsilieris, M., Russell, S. J., and Galanis, E. (2009) Engineered measles virus as a novel oncolytic therapy against prostate cancer, The Prostate 69, 82–91.
10. Msaouel, P., Iankov, I. D., Allen, C., Aderca, I., Federspiel, M. J., Tindall, D. J., Morris, J. C., Koutsilieris, M., Russell, S. J., and Galanis, E. (2009) Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter, Mol Ther 17, 2041–2048.
11. Blechacz, B., Splinter, P. L., Greiner, S., Myers, R., Peng, K. W., Federspiel, M. J., Russell, S. J., and LaRusso, N. F. (2006) Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma, Hepatology (Baltimore, Md) 44, 1465–1477.
12. Dorig, R. E., Marcil, A., Chopra, A., and Richardson, C. D. (1993) The human CD46 molecule is a receptor for measles virus (Edmonston strain), Cell 75, 295–305.
13. Naniche, D., Varior-Krishnan, G., Cervoni, F., Wild, T. F., Rossi, B., Rabourdin-Combe, C., and Gerlier, D. (1993) Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus, Journal of virology 67, 6025–6032.
14. Tatsuo, H., Ono, N., Tanaka, K., and Yanagi, Y. (2000) SLAM (CDw150) is a cellular receptor for measles virus, Nature 406, 893–897.
15. Hahm, B., Arbour, N., Naniche, D., Homann, D., Manchester, M., and Oldstone, M. B. (2003) Measles virus infects and suppresses proliferation of T lymphocytes from transgenic mice bearing human signaling lym-phocytic activation molecule, Journal of virology 77, 3505–3515.
16. Schneider-Schaulies, S., Bieback, K., Avota, E., Klagge, I., and ter Meulen, V. (2002) Regulation of gene expression in lymphocytes and antigen-presenting cells by measles virus: consequences for immunomodulation, Journal of molecular medicine (Berlin, Germany) 80, 73–85.
17. Yanagi, Y., Takeda, M., and Ohno, S. (2006) Measles virus: cellular receptors, tropism and pathogenesis, The Journal of general virology 87, 2767–2779.
18. Nussbaum, O., Broder, C. C., Moss, B., Stern, L. B., Rozenblatt, S., and Berger, E. A. (1995) Functional and structural interactions between measles virus hemagglutinin and CD46, Journal of virology 69, 3341–3349.
19. Allen, C., Paraskevakou, G., Iankov, I., Giannini, C., Schroeder, M., Sarkaria, J., Schroeder, M., Puri, R. K., Russell, S. J., and Galanis, E. (2008) Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity, Mol Ther 16, 1556–1564.
20. Nakamura, T., Peng, K. W., Harvey, M., Greiner, S., Lorimer, I. A., James, C. D., and Russell, S. J. (2005) Rescue and propagation of fully retargeted oncolytic measles viruses, Nature biotechnology 23, 209–214.
21. Paraskevakou, G., Allen, C., Nakamura, T., Zollman, P., James, C. D., Peng, K. W., Schroeder, M., Russell, S. J., and Galanis, E. (2007) Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR-or EGFRvIII expressing gliomas, Mol Ther 15, 677–686.
22. Allen, C., Vongpunsawad, S., Nakamura, T., James, C. D., Schroeder, M., Cattaneo, R., Giannini, C., Krempski, J., Peng, K. W., Goble, J. M., Uhm, J. H., Russell, S. J., and Galanis, E. (2006) Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity, Cancer research 66, 11840–11850.
23. Hasegawa, K., Nakamura, T., Harvey, M., Ikeda, Y., Oberg, A., Figini, M., Canevari, S., Hartmann, L. C., and Peng, K. W. (2006) The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer, Clin Cancer Res 12, 6170–6178.
24. Jing, Y., Tong, C., Zhang, J., Nakamura, T., Iankov, I., Russell, S. J., and Merchan, J. R. (2009) Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor, Cancer research 69, 1459–1468.
25. Hummel, H. D., Kuntz, G., Russell, S. J., Nakamura, T., Greiner, A., Einsele, H., and Topp, M. S. (2009) Genetically engineered attenuated measles virus specifically infects and kills primary multiple myeloma cells, The Journal of general virology 90, 693–701.
26. Hasegawa, K., Hu, C., Nakamura, T., Marks, J. D., Russell, S. J., and Peng, K. W. (2007) Affinity thresholds for membrane fusion triggering by viral glycoproteins, Journal of virology 81, 13149–13157.
27. Ungerechts, G., Springfeld, C., Frenzke, M. E., Lampe, J., Johnston, P. B., Parker, W. B., Sorscher, E. J., and Cattaneo, R. (2007) Lymphoma chemovirotherapy: CD20-targeted and con-vertase-armed measles virus can synergize with fludarabine, Cancer research 67, 10939–10947.
28. Hallak, L. K., Merchan, J. R., Storgard, C. M., Loftus, J. C., and Russell, S. J. (2005) Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression, Cancer research 65, 5292–5300.
29. Springfeld, C., von Messling, V., Frenzke, M., Ungerechts, G., Buchholz, C. J., and Cattaneo, R. (2006) Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases, Cancer research 66, 7694–7700.
30. Msaouel, P., Dispenzieri, A., and Galanis, E. (2009) Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview, Current opinion in molecular therapeutics 11, 43–53.
31. Vongpunsawad, S., Oezgun, N., Braun, W., and Cattaneo, R. (2004) Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM-or CD46-induced fusion and their localization on a new hemagglutinin structural model, Journal of virology 78, 302–313.
32. Nakamura, T., Peng, K. W., Vongpunsawad, S., Harvey, M., Mizuguchi, H., Hayakawa, T., Cattaneo, R., and Russell, S. J. (2004) Antibody-targeted cell fusion, Nature biotechnology 22, 331–336.
33. Radecke, F., Spielhofer, P., Schneider, H., Kaelin, K., Huber, M., Dotsch, C., Christiansen, G., and Billeter, M. A. (1995) Rescue of measles viruses from cloned DNA, The EMBO journal 14, 5773–5784.
34. Hadac, E. M., Peng, K. W., Nakamura, T., and Russell, S. J. (2004) Reengineering paramyxovirus tropism, Virology 329, 217–225.
35. Douglas, J. T., Miller, C. R., Kim, M., Dmitriev, I., Mikheeva, G., Krasnykh, V., and Curiel, D. T. (1999) A system for the propagation of adenoviral vectors with genetically modified receptor specificities, Nature biotechnology 17, 470–475.
36. Kolakofsky, D., Pelet, T., Garcin, D., Hausmann, S., Curran, J., and Roux, L. (1998) Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited, Journal of virology 72, 891–899.
37. Peng, K. W., Donovan, K. A., Schneider, U., Cattaneo, R., Lust, J., and Russell, S. J. (2003) Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker, Blood 101, 2557–2562.